Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus, Letrozole, and Metformin in Advanced or Recurrent Endometrial Carcinoma
NCT01797523Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2013
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus, letrozole, liquid metformin (Aspargo Labs) in endometrial carcinoma, sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2013; status: completed.
02
Drugs
everolimusletrozoleliquid metformin (Aspargo Labs)
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT01797523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01797523.